UnknownPHASE1, PHASE2NCT06113900

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ain Shams University
Principal Investigator
Howaida Al-Shennawi, Professor
Professor of internal medicine and Nephrology
Intervention
Dapagliflozin 10mg Tab orally once daily(drug)
Enrollment
50 enrolled
Eligibility
18-75 years · All sexes
Timeline
20232025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06113900 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials